Clinipace rejiggers eClinical platform

Clinipace has revamped its eClinical data platform, TEMPO, saying its new offering rolls disparate IT applications into one, allowing clients to cut down the cost and complexity of their clinical trials.

TEMPO is now outfitted with configurable modules, the CRO says, a set of predefined workflows, forms and reports bundled as a unit within one database. The all-in-one approach allows study teams to use exactly the applications they need without integrating systems or duplicating data, Clinipace says, and the new platform enables to clients to keep tabs on multiple trials at the same time.

With the newfangled TEMPO, clients get a cloud-based solution to organizing the mountains of data that come out of clinical trials, Clinipace CTO Daryl Porter said in a statement.

"The ability to provide cross-function and cross-trial management and visibility without excessive and expensive IT infrastructure is a huge benefit to our clients and a significant differentiator for the company," Porter said. "Through this new framework, we can more rapidly deploy innovative services that enhance quality, while creating additional efficiencies that continuously improve study visibility without lengthy development cycles."

Clinipace has more than doubled in size over the past year, and the company raised $9 million last fall to build its staff after the September acquisition of California's Paragon Biomedical. The Paragon buyout was the fourth in under three years, as the company previously snapped up CRO PFC Pharma Focus, regulatory affairs consultancy Regulus Pharmaceutical ($RGLS) and CRO Worldwide Clinical Research.

- read the statement

Suggested Articles

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.

The money will be used to expand its footprint in both China and the U.S., including a new R&D operation in Boston.